Medtronic (NYSE:MDT) Lowered to Hold Rating by Wall Street Zen

Posted by Defense World Staff on Mar 1st, 2026

Medtronic (NYSE:MDT – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

MDT has been the topic of several other research reports. Sanford C. Bernstein increased their price objective on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Royal Bank Of Canada upped their target price on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price target on shares of Medtronic in a research report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. Finally, JPMorgan Chase & Co. dropped their target price on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Read Our Latest Stock Analysis on MDT

Medtronic Trading Up 0.6%

Medtronic stock opened at $97.60 on Friday. The business has a 50 day moving average price of $98.93 and a two-hundred day moving average price of $96.89. The company has a quick ratio of 1.80, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic has a 12 month low of $79.55 and a 12 month high of $106.33. The stock has a market cap of $125.31 billion, a price-to-earnings ratio of 27.19, a price-to-earnings-growth ratio of 2.45 and a beta of 0.71.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts forecast that Medtronic will post 5.46 EPS for the current year.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by company insiders.

Institutional Trading of Medtronic

Large investors have recently made changes to their positions in the business. Curbstone Financial Management Corp lifted its position in Medtronic by 1.8% during the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock worth $537,000 after buying an additional 100 shares in the last quarter. New England Capital Financial Advisors LLC raised its stake in shares of Medtronic by 7.8% in the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock worth $135,000 after acquiring an additional 101 shares during the last quarter. Ipsen Advisor Group LLC raised its stake in shares of Medtronic by 1.7% in the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock worth $572,000 after acquiring an additional 101 shares during the last quarter. Quadrant Capital Group LLC lifted its position in shares of Medtronic by 0.3% during the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock worth $3,120,000 after purchasing an additional 101 shares in the last quarter. Finally, Baker Tilly Wealth Management LLC grew its stake in shares of Medtronic by 3.3% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock valued at $309,000 after purchasing an additional 102 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

About Medtronic

(Get Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).